AGM 2019 Presentation

November 26, 2019August 16, 2022 Alterity Therapeutics

2019

Post navigation

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2019 Presentation

Related Posts

Prana receives $3 million R&D Tax Incentive Refund

Prana receives $6.8 million R&D Tax Incentive Refund

XBRL 30 June 2024 filed with the SEC